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Abstract We studied the overall acceptability of UC781
gel formulation when applied rectally. Ten women and
twenty-six men, all HIV-uninfected, were enrolled in a
Phase 1, randomized, blinded, placebo-controlled safety
and acceptability study of the vaginal microbicide gel
UC781 applied rectally. Participants were randomized to
three groups: 0.1% UC781 gel, 0.25% UC781 gel, or a
placebo gel. Acceptability was assessed using structured
questionnaires and qualitative in-depth interviews. After
using UC781 gel rectally for seven consecutive days, par-
ticipants’ reports suggest that a UC781 gel formulation is
highly acceptable and comparable to a placebo gel. The
gels received favorable ratings overall and on attributes
such as color, smell and consistency. All of the participants
reported high intentions to use a gel like the one they used
in this study. Acceptability research is essential in early
phases of microbicide development to identify potential
problems, understand user preferences, and introduce
changes if needed.
Keywords Microbicide acceptability 
Rectal microbicides  Anal intercourse  UC781 
HIV prevention
Introduction
Microbicides are compounds that may reduce the risk of
HIV transmission during sexual intercourse and, if found
effective, may have a great impact on slowing the HIV
epidemic [1–3]. Both vaginal and rectal topical microbi-
cides are currently under development, with the former
being in more advanced stage of testing [4]. Based on
evidence that showed up-take among gay men of lubricants
containing Noxoxynol-9 (N-9), a detergent-based spermi-
cide, before it was actually tested for both safety in the
rectal compartment and efﬁcacy in preventing HIV [5], it is
generally assumed that if a vaginal microbicide were
shown to be effective, it will be used rectally by women
and men who engage in receptive anal intercourse (RAI).
Given that previous research has documented that RAI is a
common practice in a signiﬁcant proportion of the US
population [6–18] and that it is estimated to be riskier
than other sexual practices including vaginal intercourse
[19–21], testing products developed for vaginal use for
their safety in the rectal compartment is crucial [4].
To prevent HIV transmission, microbicides need not
only to be efﬁcacious and safe for people to use, but also
need to be used correctly and consistently by individuals at
risk for acquiring HIV [1, 2, 22–27]. The latter issue has
been referred to as acceptability, deﬁned as ‘‘the voluntary
sustained use of a method in the context of alternatives’’
(p. 47) [27].
To inform the development of products that ﬁt people’s
needs, past research on rectal microbicide acceptability has
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DOI 10.1007/s10461-009-9611-5mainly involved surveys of the attitudes and preferences of
men who have sex with men (MSM) about hypothetical
and surrogate products (without active agents) [1, 5, 22, 23,
28–30]. Typically, participants were informed about a
hypothetical product (level of protection provided by
condoms was sometimes presented as an anchor) and asked
their preferences about various product characteristics and
willingness to use the product in the future. In one such
study with a sample of 307 Latino MSM in NYC, 92% of
the men indicated that they would use a lubricant that could
protect against HIV transmission [1]. Studies have found
that willingness to use a hypothetical product was associ-
ated with unprotected RAI, dislike for condoms, and self-
efﬁcacy for product use [28–30]. Recognizing that there
may be variation in the formulation and amount of the
delivery vehicles that will carry an efﬁcacious agent and
the amount of volume needed to confer protection, Carb-
allo-Die ´guez and colleagues using surrogates as study
products, found that a gel is preferred over a suppository
and in volumes of up to 35 mL [22, 23] Among a small
sample of women, Exner and colleagues found that most
women were interested in a rectal microbicide [24].
To date, only one Phase 1 trial evaluated the safety and
acceptability of a product administered rectally, Advantage
24, a gel containing N-9 considered a potential microbicide
at that time [25, 31, 32]. Gross and colleagues found that
acceptability was low among the sample of monogamous,
HIV-seroconcordant male couples; less than half reported
intentions to use it in the future if it were approved for
rectal use [25]. Participants reported rectal fullness and
discomfort with most of the complaints involving insertion
of the applicator, its sharp edge at the tip, and dispensing of
air with the gel. Other complaints involved comments
about the gel being too sticky and drying out too quickly;
having an unappealing taste, smell, and color. Furthermore,
although the initial studies did not identify safety problems
[31], subsequent studies concluded that N-9 causes epi-
thelial disruption increasing susceptibility to HIV infection
and thus, placing individuals at increased risk for con-
tracting HIV [33, 34].
Based on prior research, several factors have been
identiﬁed as salient and appropriate in assessing accept-
ability comprehensively at each phase of product devel-
opment [26]. For Phase 1 trials, those factors are: (1)
formulation-associated variables, such as texture and vis-
cosity, product scent, color, and taste, and desirable/
appealing elements of formulation; (2) application-associ-
ated variables, such as ability to adhere to instructions, ease
of product preparation (e.g., ﬁlling applicator with prod-
uct), ease of application, portability, applicator design and
disposal preferences; (3) use-associated variables, such as
frequency and timing of product use, partner-speciﬁc
issues, lubrication, product consistency post-use, desirable/
appealing elements of use, use with/without condom,
changes in hygiene practices secondary to use, and changes
in sexual pleasure secondary to use; and (4) related
covariates, such as history of vaginal and anal product use,
frequency of vaginal and anal sex, relationship ‘‘har-
mony’’; relationship communication. Assessing accept-
ability together with determining the clinical safety proﬁle
of products is recognized as crucial in early phases of
microbicide trials [22, 23, 26]. Lack of acceptability of a
product in early stages of development would raise an
important alert for scientists to retool the product, its
delivery system or mode of use before embarking on larger
and more expensive efﬁcacy studies.
In this Phase 1 randomized, blinded, placebo-controlled
trial, we evaluated the vaginal microbicide candidate,
UC781 (CONRAD, Arlington, VA), a non-nucleoside
reverse transcriptase inhibitor (NNRTI) of the HIV-1
reverse transcriptase (RT) enzyme [35], when administered
rectally as a gel in HIV-1 uninfected adults [36]. In this
report, we compare participants’ product-use ratings in
three treatment groups (0.1% UC781 gel, 0.25% UC781
gel, or a placebo gel) to examine what factors contribute to
or detract from acceptability of UC781 applied rectally
among women and men. Our hypothesis was that after one
week of practice in the use of the product, respondents
would, on average, report high intentionality, deﬁned as an
average score in the upper one-third of the Likert scale, to
use the product in the future every time they have receptive
anal intercourse. Furthermore, participants would report
high intentionality to use the product on occasions when
they do not use condoms. Additionally, we anticipated that,
although many of the individuals who voluntarily enroll in a
study like ours would be predisposed to like the product (as
measured at baseline), the experience of using the gel would
on average increase their intentionality ratings. We did not
anticipate differences among the three groups in intention-
ality to use the product in the future, since the placebo used
in this study from the investigator’s point of view, was quite
similar to the formulation for the UC781 gel.
Methods
Participants
A Phase 1 randomized, blinded, placebo-controlled trial
was conducted at the Center for HIV Prevention Research at
David Geffen School of Medicine at UCLA, Los Angeles,
CA, USA, between December 2007 and April 2008. HIV-
uninfected women and men were recruited using four
strategies: (1) clinician-patient referrals; (2) use of existing
study registries that contain contact information of indi-
viduals who gave informed consent to be reached for future
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friends or partners who may meet eligibility criteria); and
(4) study advertisements. Individuals were eligible to par-
ticipate if they met the following criteria: (1) 18 years of
age or older; (2) reported a history of consensual RAI at
least once in lifetime; (3) received a negative HIV antibody
test and STI tests (for N. gonorrhea, C. trachomatis,
syphilis and active HSV disease) at screening; (4) being in
good health as assessed by a physical examination, and not
meeting any exclusionary criteria (e.g., history of signiﬁ-
cant gastrointestinal bleeding, allergies to methylparaben,
propylparaben, sorbic acid, use of certain medications); and
(5) not having a history of alcoholism or injection drug use.
Participants also had to be willing to abstain from insertion
of anything per rectum other than the study gel, including
abstaining from RAI, 1 week prior to treatment, 1 week
prior and after each ﬂexible sigmoidoscopy, as well as
abstain from chronic use of aspirin and non-steroidal anti-
inﬂammatory drugs (e.g., Advil). In addition, women had to
receive a negative pregnancy test, not breastfeed, and be
post-menopausal or use an acceptable form of contraception
(e.g., barrier method, IUD, hormonal contraception, surgi-
cal sterilization, or vasectomization of male partner).
Procedures
A detailed description of study procedures as they pertain
to the safety aim of the study exceeds the scope of this
publication and will be presented elsewhere [36]. In terms
of the behavioral evaluations, individuals who were
deemed eligible after the screening period took part in a
structured assessment, the Baseline Behavioral Question-
naire administered by Web-based, Computer Assisted Self-
Interview (CASI). Participants were given the option of
completing the questionnaires over the Internet at any
location convenient to them. Those without access to a
computer or the Internet completed the questionnaires at
the study site. Participants were provided with assistance,
as needed.
A total of 36 HIV-uninfected participants (10 women
and 26 men) were randomized to one of three groups: 0.1%
UC781 gel, 0.25% UC781 gel, or a placebo gel (12 per
group). UC781 0.1% and UC781 0.25% gels are off-white
to light yellow aqueous formulations containing, respec-
tively, 0.1 or 0.25% (w/w) UC781, Carbomer 974P,
methylcellulose, glycerin, puriﬁed water and common
preservatives (methylparaben and propylparaben). Both 0.1
and 0.25% UC781 strength gels were adjusted to pH 5.2.
The placebo gel, hydroxyethyl cellulose (HEC), is a clear
aqueous gel formulation containing non-active substances:
sodium chloride, hydroxyethyl cellulose, sorbic acid,
sodium hydroxide and puriﬁed water. All three gels were
similar to the touch for investigators, although viscosity
differed markedly. The volume of each dose was 3.5 g
(approximately 3.5 mL).
Study gels were packaged in an overwrapped, single
dose, preﬁlled vaginal applicator that had been designed
and FDA-approved for use in the vaginal microbicide
clinical trials of UC781 [37]; this was not a rectal-speciﬁc
applicator design. The single-use vaginal applicator con-
sists of a barrel and plunger with a screw-on cap [38]. The
barrel measures 114 mm long by 12.7 mm wide with a
tapered and rounded tip and a ﬂanged base. Applicators
were labeled with ‘‘Caution: New Drug—Limited by
Federal (United States) law to investigational use.’’ Seven
applicators were dispensed in a single box that included an
instructional pamphlet with diagrams to depict proper
insertion. A single, blinded label was afﬁxed to each box
with the following information: randomization number,
protocol number, storage conditions and dosing instruc-
tions. Only the investigational pharmacy was unblinded to
group throughout the study.
Once randomized, study staff administered a single dose
of the study gel after a preparatory Normosol-R pH 7.4
enema. Participants had the option of lying on their side,
ﬂat on their back with knees bended, or standing and
bending over. After a 7-day wash-out period, study staff
reviewed the instructions with participants before dis-
pensing the 7-day supply for home use. Participants self-
administered once daily outpatient doses of the study gel
for 7 days and then completed a Product Acceptability
Questionnaire via Web-based CASI. After completing all
study procedures (three separate ﬂexible sigmoidoscopies
and multiple other mucosal irritation assessments), partic-
ipants took part in a semi-structured phone interview
conducted by a gender-matched interviewer (either a male
interviewer for a male participant, or a female interviewer
for a female participant) with experience in rectal micro-
bicide research. On average, the interviews lasted 35 min.
Participants completed six study visits and were com-
pensated a total of $750 in cash for their time. To
encourage completion of the trial, participants were paid
more toward the end of the trial. No compensation was
provided for the eligibility screening.
Measures
Questionnaires were posted on a Web page accessible to
study participants with a username and password. The
purpose of using this assessment method was to accom-
modate participants’ needs and, at the same time, to
encourage them to be as honest as possible in their
reporting, minimizing a need to conform to an inter-
viewer’s expectations in a face-to-face encounter. To
minimize missing data due to browsing from screen to
screen too quickly, a ‘‘Prefer not to answer’’ option was
620 AIDS Behav (2010) 14:618–628
123presented for every questionnaire item to identify pur-
posely skipped questions. All participants completed the
Web-based questionnaires.
Baseline Behavioral Questionnaire
Sexual Behavior Participants were asked to report their
sexual behavior during the previous two months, including
number of sexual partners and unprotected RAI occasions.
Questions were posed both in formal and vernacular lan-
guage to increase comprehension.
Rectal Microbicide Intentions At baseline, we asked: ‘‘If
a rectal microbicide were available that provided some
protection against HIV, and it were presented as a gel, how
likely would you be to use it every time you have anal
intercourse?’’ The response scale ranged from 1 =
‘‘Extremely unlikely’’ to 10 = ‘‘Extremely likely’’.
Product Acceptability Questionnaire
The acceptability assessment, completed once participants
ﬁnished using the study product, included a general ques-
tion (‘‘Overall, –i.e., considering all the episodes in which
you used this gel—how much did you like the product?’’);
it also included speciﬁc questions on the level of like/dis-
like of the products’ physical properties, application pro-
cess, and applicator. Participants responded to these
questions on a 10-point Likert scale (1 = ‘‘Disliked very
much’’ to 10 = ‘‘Liked very much’’). They were asked
speciﬁcally about how the product felt inside their rectum
(‘‘How much did you like how the gel felt inside your
rectum [immediately after inserting it/30 min after insert-
ing it]?’’) Given that participants were asked to refrain
from engaging in receptive anal intercourse during the
study, we did not assess product-use acceptability in the
context of sexual intercourse. However, participants were
presented hypothetical situations such as, ‘‘If a gel were
available that contributed to provide some protection
against HIV, and it looked like the one you have used in
this study, how likely would you be to use it every time you
have anal intercourse?’’, ‘‘How likely would you be to use
a gel that contributed to provide some protection against
HIV on the occasions when you don’t use condoms?’’, and
‘‘How likely would you be to use a gel if you had to wait
30 min after application before having intercourse?’’, as
well as ‘‘How much would you be willing to spend on a gel
per sexual occasion?’’ (1 = ‘‘About as much as one spends
on condoms’’ to 3 = ‘‘Three times as much’’). Participants
were also asked whether they had used a volume different
than the one recommended (each pre-ﬁlled applicator
contained 3.5 mL of gel), and if any problems were
experienced (e.g., leakage, soiling of underwear or linens);
for those experiencing problems, we asked how bother-
some they were (1 = ‘‘Not at all’’ to 10 = ‘‘Very much’’).
Finally, participants were asked about their willingness to
use a higher volume and whether they had any product
recommendations.
Semi-Structured Interview
After reviewing the responses the participants provided to
the Web-based CASI, gender-matched interviewers con-
ducted a phone interview with each participant during
which the speciﬁc circumstances of product use for the
‘‘home assignment’’ were explored. Interviewers sought to
clarify any discrepancies that might have been observed in
the reported quantitative data, as well as to contextualize
the quantitative reports. All interviews were audio recorded
and transcribed.
Data Analysis
To account for non-normal data, Kruskal–Wallis non-
parametric tests were used to evaluate whether the ratings
were signiﬁcantly different by group (0.1% UC781 gel,
0.25% UC781 gel, or a placebo gel). The qualitative data
were coded based on the structure of the interview guide
that covered topics such as opinions about the gel, appli-
cator, administration process, and use-associated variables.
Coded passages were summarized and quotes that illus-
trated speciﬁc topics were selected to complement the
quantitative data.
Results
Sample Description
Ten women and 26 men completed the trial. Participants
ranged in age from 24 to 64 years (M = 41.70,
SD = 10.99). Three-quarters completed a high school
education or higher; half were employed either full or part-
time, having a median annual income in the $10,001-
$20,000 range; nearly two-thirds identiﬁed as being of
ethnic minority background (14 participants identiﬁed as
African-American, 5 as Latino, 1 as Asian or Paciﬁc
Islander, and 1 as Native American; 14 identiﬁed as White
or European American); and over three-quarters of the men
identiﬁed as gay and nearly three-quarters of the women
identiﬁed as straight.
Sexual Behavior
Among the male participants, one completed the wrong
version of the sexual behavior questionnaire; data for this
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(18 of 25) of the male participants reported having had at
least one male sexual partner (Mdn = 2.00) in the prior
2 months with whom they had engaged in anal intercourse.
Forty percent (n = 10) of the participants reported having
engaged in RAI and 60% (n = 15) in insertive anal inter-
course in the previous 2 months. On average, participants
reported having 4.72 (Mdn = 1.00) occasions of RAI in the
previous two months, slightly more than half (55.1%) of
them unprotected. Slightly more than three-quarters
(78.7%) of the insertive anal intercourse occasions
(Mdn = 1.00, M = 14.37, SD = 45.48) in the previous
2 months were unprotected.
Half of the male participants who reported having had at
least one female sexual partner in the previous 2 months
(n = 10; M = 1.42, SD = 2.70), reported engaging in anal
intercourse with their female partners. All but one of the
ten anal intercourse occasions reported were unprotected.
Similarly, the majority of the total vaginal intercourse
occasions were unprotected.
Among the female participants, 5 of the 10 women
reported having had at least one male sexual partner
(Mdn = 1.00) in the previous 2 months. Three reported
engaging in anal intercourse; half of the total anal inter-
course occasions reported (10) were unprotected.
Product Acceptability
Kruskal–Wallis non-parametric tests were used to evaluate
whether the ratings were signiﬁcantly different by condi-
tion (Table 1). As expected since the study gels were
similar to the touch, our ﬁndings showed that there were no
statistically signiﬁcant group differences in the accept-
ability ratings of the two UC781 (0.1 and 0.25%) gels as
compared to the placebo gel. Similar ratings were observed
between women and men. Because of concerns of insufﬁ-
cient statistical power to detect differences and in order to
get an estimate of the magnitude of the effect, we examined
eta-squared (g
2) from the ANOVAs (see Table 1) to get a
measure of the relationship between each acceptability
variable (dependent variable) and the treatment group
(independent variable). Eta-squared is the proportion of
variance that is attributable to the treatment condition. For
example, ratings for being bothered by soiling of under-
wear or linens were higher among the three men who
reported soiling in the placebo group (M = 4.00,
SD = 1.00) as compared to the four men in the 0.1%
UC781 group (M = 2.50, SD = 1.29). However, because
of the small sample size in each group, this test was not
statistically signiﬁcant (g
2 = .529).
For descriptive purposes, we combined results across the
three gel conditions to describe overall acceptability and
ratings on formulation, application, and use.
Overall Product Ratings
Overall, the majority of participants (56%; 20 out of 36;
95% conﬁdence interval (CI), .40–.71) reported liking the
product used in this study (ratings were in the upper third
of the 10-point scale), irrespective of condition. The
remainder of the sample felt neutral, indicating that overall,
they neither disliked nor liked the product. During the
semi-structured interview, one participant explained his
reasons for a high rating:
I felt that the product was more practical than lubri-
cants that I’d been using in the past because it wasn’t
as messy, it didn’t stick to my ﬁngers, it wasn’t
oily… and could be applied directly. (ID 452, 0.1%
UC781 gel, male)
It is important to note that participants rated the product
after they had had the opportunity to use it repeatedly.
Familiarity with the product, applicator, and mode of
administration gained in successive days may have had a
positive effect on the ﬁnal rating.
[At the beginning] I was making myself nervous
doing it. ‘‘I have to get it out of the box, open it,
plunger in, make sure I do it right, make sure I don’t
let any [gel] come out.’’ … I got more comfortable
with it over the days… [In the end,] it took a little
over a minute. (ID 444, 0.25% UC781 gel, male)
Formulation-Associated Factors
Participants reported liking the product’s color (62%; 21
out of 34 who provided a rating; 95% CI, .45–.77), smell
(55%; 6 out of 11; 95% CI, .27–.80), taste (57%; 4 out of 7;
95% CI, .23–.86), and consistency (61%; 22 of 36; 95% CI,
.44–.75). Only one male participant indicated disliking
both the color and consistency of the study product (pla-
cebo gel). Another male participant (0.1% UC781 gel)
reported disliking its consistency and a female participant
disliked its color (0.1% UC781 gel). The remaining par-
ticipants felt neutral, indicating they neither disliked nor
liked the product’s attributes.
In the semi-structured interview, some participants fur-
ther described what they liked about the product they tried:
I never felt it on my hands, I never felt greasy, I never
felt really the residue of it. (ID 408, 0.1% UC781 gel,
male)
Even days after I put it in there, I didn’t get no
reaction, no allergy reaction, and I’m from [name of
island]. I get allergy rashes from the water here. But I
didn’t get any kind of reaction at all from the gel. (ID
439, 0.1% UC781 gel, male)
622 AIDS Behav (2010) 14:618–628
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123Others reported that, initially, the gel felt cold (ID 424,
0.1% UC781 gel, female) or that it burned (ID 410, 0.1%
UC781 gel, female), but the sensations disappeared when
the participants became familiar with the product.
The ﬁrst time I tried it, I had a little bit of ardor. It
was stingy a little too much. But I think it was my… I
had had some hot peppers for dinner, so I wasn’t sure
which was causing that… After that day, I never had
that problem anymore. (ID 451, placebo gel, male)
Application-Associated Factors
Fewer participants rated the process of applying the study
product favorably (36%; 13 out of 36; 95% CI, .22–.53);
the majority felt neutral about it (neither disliked it nor
liked). Seventy-two percent (95% CI, .55–.84) rated dis-
pensing the product as very easy; only one participant
(0.25% UC781 gel) reported it as difﬁcult. Although the
average rating for the applicator was in the upper third of
the scale (58%; 21 out of 36; 95% CI, .42–.73), four par-
ticipants (1 woman and 3 men) reported disliking it. Four
male participants indicated that it would be difﬁcult to
carry the product applicator around. Eighty-one percent
(95% CI, .65–.91) favored a disposable product, such as the
one used in the study, over a reﬁllable one.
During the semi-structured interviews, some participants
stated that they had no complaint at all about the applicator
or the application process, ‘‘It’s compact, and portable, and
easy enough to use’’ (ID 418, 0.1% UC781 gel, male).
However, several others explained that they experienced
problems using rectally an applicator that was designed for
vaginal use. The vaginal applicator elicited complaints
even after a lubricant was used to facilitate insertion:
[U]sually I only do enemas occasionally you know,
just for general health purposes, to keep my inside
clean. […] I don’t use the lubricant with that [tip of
enema delivery system], cause it’s too small and it’s
really smooth and just hasn’t presented any problems.
But with the gel for the study I deﬁnitely needed to
use a lubricant because that was– just the tip of the
applicator is a little big. […] You know, it would be
uncomfortable without it [lubricant]. (ID 405, 0.25%
UC781 gel, female)
The only problem I had with it is the applicator itself
becausethetopisopenyouknow.And,whenyouputit
in, it like hurts the walls when you’re inserting it. My
suggestionthatItoldthedoctorthatiftheymadeitmore
round, like Tampax applicators are and make it easier
for it to go in. (ID 427, 0.25% UC781 gel, female)
Other problems with the applicator included difﬁculty in
handling it while trying to insert the study product and not
having tactile indicators to signal both when the applicator
was sufﬁciently inserted in the rectum and that all of the
gel was ejected.
I could see some dudes kind of drunk or high or
whatever shoving the whole thing up there, and then
you have to worry about getting it out. [You need to]
have like a grip mark on it and that’s where your
ﬁngers go, and above that is how far it’s supposed to
go up your butt. (ID 455, placebo gel, male)
For one participant, applicator-related problems resulted in
using less than the speciﬁed amount of gel on two
occasions.
When I was pushing on the thing, […] whatever the
name of those two pieces of plastic [is], the long
skinny piece [plunger] through the other piece [bar-
rel], I couldn’t tell if it was completely at the end.
[…] The thing [applicator] wasn’t big enough to hold
on to and to push in on it….I found the applicators a
little cumbersome. It was a little wide and it seemed a
little hard to push the… It seems as if it needs a little
thing on the end where you pose your ﬁngers on. (ID
408, 0.1% UC781 gel, male)
Having to unwrap and assemble the applicator were other
complications mentioned by participants, particularly in
the initial use of the study product at home.
I realize they have to keep it fresh and unopened, but
I couldn’t get the package… I had to use my ﬁn-
gernail clippers a few times to open it. (ID 408, 0.1%
UC781 gel, male)
I had a hard time the ﬁrst time. I forgot everything
that the staff told me. So the next day, I took off the
little cover [cap] and put the syringe [plunger] in, and
then some gel popped out. But I shoved it in there
anyway. … The next day, I read the paper again, and
they said ‘‘leave the blue cap on, then put the plunger
until you hear a click, and then take the cap off.’’ (ID
439, 0.1% UC781 gel, male)
Concerning the position when applying the product, some
participants felt more comfortable doing it while standing
up while others preferred to be lying down, on their side, or
squatting.
My ﬁrst time I tried it I was standing… It was difﬁ-
cult. The second time, I was lying down and it was
much easier. And by the third time, I was almost a
pro. (ID 430, 0.1% UC781 gel, female)
I was lying down on my bed and entered it with my
legs up in the air. I think a little bit fell out because I
wasn’t really sure how I was going to do it. [Then I
said,] ‘I’m going to do it in a squatting position
624 AIDS Behav (2010) 14:618–628
123because none of it slipped out that time.’ And I
continued to do it in a squatting position all the way
through. (ID 432, placebo gel, female)
Participants indicated that any initial problems they
experienced with applying the study product were over-
come with practice.
It became easier and easier to do it [insert the prod-
uct] and then I actually [could] do it in a public
restroom. (ID 439, 0.1% UC781 gel, male)
Use-Associated Factors
Participants rated the study product favorably on its feeling
in the rectum immediately after insertion (54%; 19 out of
35; 95% CI, .38–.70) and/or 30 min after insertion (49%;
17 out of 35; 95% CI, .33–.65). Of the remaining partici-
pants, all but two felt neutral about how the study gel felt
inside the rectum after insertion and after 30 min had
passed. One participant disliked how the placebo felt inside
the rectum after insertion and after 30 min had passed. In
addition, one participant disliked how 0.1% UC781 felt
after 30 min passed. The majority (across the three con-
ditions) felt that the study product was absorbed in their gut
(55%; 16 out of 29; 95% CI, .37–.72). Some leakage was
reported by 36% of the sample across the three conditions
(13 out of 36; 95% CI, .22–.53) but they were bothered
very little by it. Soiling of underwear and linens was
reported by a little over a ﬁfth of the sample (8 out of 36;
95% CI, .11–.38).
In the semi-structured interview, participants
explained,
Before I used it, I thought, ‘‘Oh, this is going to be a
big mess, it’s going to be goopy everywhere; it’s
gonna take a while to get rid of it.’’ And I used it
[and] it was a very easy process. A couple of times
[there was] leaking, but the leaking seemed very li-
quidy, as compared to gooey. It’s the reason that I
thought if it [were] thicker, maybe it wouldn’t do
that. (ID 408, 0.1% UC781 gel, male)
When I would put it in, I don’t know whether it was
my nerves or whether it was the gel, but I would get
the sensation that there was something in my butt and
I would feel like pushing. I would get a lot of ﬂatu-
lence and I would feel something come out, but I
don’t know if it was speciﬁcally the gel. (ID 444,
0.25% UC781 gel, male)
By contrast, another participant stated,
It did not feel any different than using just regular
lube, of K-Y. (ID 422, 0.1% UC781 gel, male).
Recommendations
Most of the product recommendations were related to the
applicator. In this study, a vaginal applicator was used to
administer the study gel rectally. Suggestions included
making the applicator smaller, making the tip thinner and
softer speciﬁcally for rectal use, changing the tip to reduce
the chance of accidental poking of rectal wall, making it
easier to grip and requiring no user-assembly (inserting the
plunger in the barrel), and adding a small packet with
lubricant in the package to help with insertion. A few par-
ticipantssuggestedmakingthegelthickerandlessrunny(‘‘it
should be the consistency of cold pie ﬁlling or cold Cool
Whip’’), and adding various ﬂavors (none were suggested).
A compact (‘‘just like condoms’’), stylish and appealing
(‘‘not medical appearing’’), and ‘‘eco-friendly and bio-
degradable package’’ was suggested. Participants stated,
Carrying it becomes difﬁcult, especially if you are a
man. What are you gonna do? Put it in your wallet?
… It is much easier to carry a condom than that. (ID
420, 0.25% UC781, male).
[The applicator] is kind of noticeable. … There is still
stigma if people could tell you had a condom in your
pocket. ‘‘This is a big slut,’’ written across your
forehead (ID 444, 0.25% UC781 gel, male).
Intention to Use Gel in the Future
As expected, after participants used the study product,
there was no statistically signiﬁcant difference in inten-
tionality to use the product in the future among the three
groups. All of the participants rated their intention in the
upper third of the Likert scale (‘‘extremely likely’’) after
they had a chance to use the study product. Although not
statistically signiﬁcant (Wilcoxon Signed-Rank Test
z = 1.09, P = .28), intention to use the gel in the future
increased with respect to the intention reported prior to any
rectal experience with the gel (baseline: M = 7.88,
SD = 3.55; post-trial: M = 8.66, SD = 2.31). Participants
reported high intentions to use a gel on occasions when
condoms are not used and if a 30-min wait time was
required for a microbicide to take effect before they could
engage in anal intercourse.
In the semi-structured interviews, some people qualiﬁed
their enthusiasm for the product: ‘‘It would be easy [to use]
but it probably depends on the heat of the moment. Ain’t
nobody always stop and do that’’ (ID 410, 0.1% UC781
gel, female). When asked about having to wait 30 min after
application before having sex, a participant said, ‘‘If you
have to put any time limit, it doesn’t work as well’’ (ID
425, 0.1% UC781 gel, male).
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123When asked about using a product with sexual partners,
participants did not consider it an issue:
Anything that would prevent something or … creates
a positive environment for sex would be all, they’d
[referring to female partners] be all over it (ID 425,
0.1% UC781 gel, male).
I know he will like it, especially if it will prevent
disease (ID 420, 0.25% UC781 gel, male).
Using a lubricant would be way easier than putting on
something that you don’t really feel comfortable with
(ID 417, placebo gel, male).
Almost all of the participants would be willing to use a
microbicide even if half or twice as much as used in this
study were required. The majority would be willing to
spend as much as one spends for condoms; 25% would be
willing to spend twice as much as condoms.
Discussion
This is one of the ﬁrst studies in which a microbicide can-
didate, formulated and designed for vaginal use, was used
rectally on several occasions by an ethnically diverse
sample of HIV-uninfected women and men who reported at
least one occasion of RAI in their lifetime. Given that the
majority of participants reported having had anal inter-
course, frequently unprotected, in the 2 months prior to the
interview, our sample appears to be drawn from the popu-
lation most likely to beneﬁt from the future availability of
an effective rectal microbicide. After using UC781 gel
rectally for 7 days, all of the participants reported high
intentions to use a product like the one used in this study in
the future. Participants’ reports suggest that this gel for-
mulation of UC781 is highly acceptable and comparable to
a placebo gel. The product was rated high by a majority of
participants overall and on attributes such as color, smell,
and consistency. Only two participants reported using less
than the speciﬁed amount and a few reported being bothered
by leakage and soiling of their underwear or linens. Con-
sidering together the different acceptability aspects asses-
sed, this study by both women and men suggests that rectal
use of a gel formulation of UC781 would be acceptable.
In the semi-structured interviews it was elucidated that
people monitor themselves closely when they start using a
product, attributing discomfort to the product rather than
alternative sources (e.g., having eaten hot peppers). In the
initial use of the study product, participants were concerned
about administering it as instructed and using the required
dose, as well as how the product felt (greasy, gooey) or
behaved (the product is liquid and, therefore, leaks). It was
not until participants had several tries at using the study
product that they felt comfortable with it, which points out
the importance of encouraging repeated use before eliciting
opinions (unless participants ﬁnd the product completely
unacceptable on their ﬁrst trial, in which case they should
not be required to continue using it). More data are needed
to determine the number of tries it may take individuals, on
average, to feel comfortable inserting and dispensing a
product.
From a methodological point of view, the combined use
of quantitative and qualitative assessment tools proved
quite rich. We were able to establish that although partici-
pants felt positive or neutral in their quantitative ratings of
the application process and the applicator, when given the
opportunity to elaborate, during the qualitative interviews,
they pointed out a number of ways in which the applicator
and its wrapper could be improved. This is useful infor-
mation to take into account for the design of a rectal-spe-
ciﬁc applicator as well as to anticipate (and correct)
situations that may interfere with adherence not just in
Phase 1 clinical trials but also in larger Phase 2 or 3 trials. A
complicated issue that needs attention is portability: Indi-
viduals who may want to take the product with them are
likely to prefer a non-conspicuous presentation, something
difﬁcult to achieve if an applicator is required for delivery
of the microbicide intrarectally. The appearance of the
applicator used in this study is one intended for vaginal use,
similar to that of a tampon and therefore participants may
have had, a priori, negative associations for its use.
While our ﬁndings offer important acceptability data
about this microbicide candidate, there are several study
limitations that need to be noted. First, because this study
was a clinical safety trial with a small sample size and
speciﬁc eligibility criteria, data may not be generalizable to
other populations. In addition, participants were volunteers
who may differ in untold ways from the general population
who may use (or not) the product in the future. Also,
participants were asked to use the product at home for only
7 days; acceptability could be different if the product were
used over a longer period of time. Participants may be
responding to social desirability in their responses to
questionnaires. Furthermore, participants did not try the
product in the context of anal sex. Therefore, we are una-
ware how sexual pleasure or partners’ reactions, including
any penile reactions or symptoms, may affect the accept-
ability of a product.
We assessed acceptability in the context of a clinical trial
that involved a speciﬁc dosing regimen (product had to be
used once daily for 7 days) and other restrictions (many
inclusion and exclusion criteria, and refraining from anal
intercourse during the study) that did not represent ‘‘real
world’’ use. Nevertheless, a microbicide formulated as a gel
has been thought to be amenable particularly to gay men
because it could be easily incorporated into routines and
practices that already accompany anal sex [5, 22, 23, 39,
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12340]. Prior research indicates that most MSM use lubricants
and douches or enemas in preparation for anal intercourse
[1, 5, 40]. Although there is evidence that there is variation
in women’s preferences for vaginal lubrication [41], very
little is known about rectal lubrication and douching prac-
tices in preparation for anal intercourse among women [24].
More research is needed to understand how current routines
and practices that are concurrent with anal intercourse will
impact whether a product is found acceptable among
women and men.
In summary, we collected acceptability data on UC781
gel, provided participants with the opportunity to elaborate
on their ratings of the product, and found no serious
acceptability problems that would make it advisable to
introduce signiﬁcant changes in the development path for
this product. Acceptability research is essential in early
phases of microbicide development to aid in understanding
user preferences for a product. Making changes to a
product earlier rather than later in development will reduce
the total cost of development signiﬁcantly and ultimately
achieve the desired outcome, increased use of a product
that would decrease the global burden of HIV. However, it
is imperative to assess acceptability of this candidate over a
longer period of time and concurrent with anal intercourse,
as behavioral and contextual factors could shape microbi-
cide acceptability and therefore inﬂuence up-take and
continued use by individuals [26, 27].
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